Aptevo Therapeutics Inc.
APVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671584
No open-market purchases or sales by Aptevo Therapeutics Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $224.3K in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Aptevo Therapeutics Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- −19 vs. Q4 2023
- Shares held
- 2.64K
- −1.93M (−99.9%) vs. Q4 2023
- Total value
- $12.4K
- −$337.3K (−96.5%) vs. Q4 2023
- New holders
- 1
- 1 more added
- Sold out
- 20
- 8 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting APVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $224.3K |
| Q1 2026 | 9 | $229.7K |
| Q4 2025 | 11 | $191.4K |
| Q3 2025 | 12 | $717.1K |
| Q2 2025 | 7 | $45.9K |
| Q1 2025 | 8 | $22.8K |
| Q4 2024 | 13 | $208.7K |
| Q3 2024 | 19 | $231.1K |
| Q2 2024 | 18 | $599.1K |
| Q1 2024 | 10 | $12.4K |
| Q4 2023 | 29 | $349.7K |
| Q3 2023 | 26 | $1.13M |
| Q2 2023 | 23 | $1.36M |
| Q1 2023 | 24 | $1.82M |
| Q4 2022 | 27 | $2.27M |
| Q3 2022 | 27 | $2.63M |
| Q2 2022 | 27 | $2.85M |
| Q1 2022 | 24 | $4.76M |
| Q4 2021 | 23 | $5.99M |
| Q3 2021 | 26 | $42.1M |
| Q2 2021 | 29 | $65.5M |
| Q1 2021 | 34 | $89.7M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Aptevo Therapeutics Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 1,324 | $6.21K | 0.00% | −12,336−90.3% | Reduced |
| BlackRock Inc. | 890 | $4.17K | 0.00% | −45,745−98.1% | Reduced |
| Morgan Stanley | 194 | $910 | 0.00% | −11,176−98.3% | Reduced |
| Qube Research & Technologies Ltd | 100 | $469 | 0.00% | +100 | New |
| Advisor Group Holdings, Inc. | 45 | $211 | 0.00% | +15+50.0% | Added |
| JPMorgan Chase & Co | 43 | $202 | 0.00% | −1,854−97.7% | Reduced |
| Wells Fargo & Company | 36 | $169 | 0.00% | −1,581−97.8% | Reduced |
| Fifth Third Bancorp | 6 | $28 | 0.00% | −285−97.9% | Reduced |
| The PNC Financial Services Group, Inc. | 3 | $14 | 0.00% | −139−97.9% | Reduced |
| Truvestments Capital LLC | 2 | $9 | 0.00% | −93−97.9% | Reduced |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −516,789−100.0% | Sold out |
| Sabby Management, LLC | 0 | $0 | 0.00% | −349,471−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −262,124−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −159,000−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −138,697−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −104,608−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −91,725−100.0% | Sold out |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −61,130−100.0% | Sold out |
| Cantor Fitzgerald, L. P. | 0 | $0 | 0.00% | −58,532−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −43,201−100.0% | Sold out |
| Northern Trust Corp | 0 | $0 | 0.00% | −14,121−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −11,248−100.0% | Sold out |
| Baader Bank INC | 0 | $0 | 0.00% | −15,086−100.0% | Sold out |
| Franklin Resources Inc | 0 | $0 | 0.00% | −10,997−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −10,941−100.0% | Sold out |
| Divergent Wealth Advisors, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −17−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −5−100.0% | Sold out |